# VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)

Study · id `cardio:ct-nct07516444` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07516444](<https://clinicaltrials.gov/study/NCT07516444>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07516444

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 520 participants.

## Technical summary

Registry record NCT07516444. Randomized; single masking; primary purpose treatment. Start 2026-07-28 (actual); primary completion 2029-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 520 participants (planned count; ClinicalTrials.gov record NCT07516444, source copy `cardio:ctgov-nct07516444-2026-11-10`, retrieved 2026-11-18)
- Started: 2026-07-28 (actual) (ClinicalTrials.gov record NCT07516444, source copy `cardio:ctgov-nct07516444-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07516444, source copy `cardio:ctgov-nct07516444-2026-11-10`, retrieved 2026-11-18)
- Completion: 2036-06 (anticipated) (ClinicalTrials.gov record NCT07516444, source copy `cardio:ctgov-nct07516444-2026-11-10`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07516444, source copy `cardio:ctgov-nct07516444-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07516444-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
- Acronym: TRIVITA
- Condition: Tricuspid Valve Regurgitation
- Condition: Tricuspid Valve Disease
- Condition: Cardiovascular Diseases (CVD)
- Condition: Heart Valve Diseases
- Condition: Tricuspid Valve Insufficiency
- Condition: Severe Heart Valve Disease
- Condition: Randomized Controlled Trial (RCT)
- Condition: Symptomatic Tricuspid Regurgitation
- Intervention (Device): Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System
- Intervention (Device): Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System
- Lead sponsor: VDyne, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)

## Provenance

Content hash: 4e3463bbbf872723b1285518800b04a6f458f204523e9d149b89f233c188d073
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
